remedie regenerative medicine remedie regenerative
play

REMEDiE: Regenerative Medicine REMEDiE: Regenerative Medicine in - PowerPoint PPT Presentation

REMEDiE: Regenerative Medicine REMEDiE: Regenerative Medicine in Europe p Final International Conference, Final International Conference, Bilbao, Spain, April 18 19 2011 REMEDiE: Introduction Professor Andrew Webster Professor Andrew Webster


  1. REMEDiE: Regenerative Medicine REMEDiE: Regenerative Medicine in Europe p Final International Conference, Final International Conference, Bilbao, Spain, April 18 ‐ 19 2011

  2. REMEDiE: Introduction Professor Andrew Webster Professor Andrew Webster Final International Conference, Bilb Bilbao, Spain, April 18 ‐ 19 2011 S i A il 18 19 2011

  3. Principal objectives of REMEDiE Principal objectives of REMEDiE • A detailed examination of the political economy of A d il d i i f h li i l f globalised regenerative medicine, applying this to highly significant policy and public issues within highly significant policy and public issues within Europe • An integrated series of projects organised around • An integrated series of projects organised around three inter ‐ related streams of research – markets, politics bioethics politics, bioethics • The development of a global database to identify global (inter ‐ related) trends and to map these global (inter related) trends and to map these

  4. www.york.ac.uk/satsu/remedie y / /

  5. Some key developments over past 3 years in the RM field The science : rapid scientific engagement with iPS reprogramming of adult cells from one cell type to another p g g yp genomic sequencing to determine pluripotency and so aid manipulation of cells tracking systems for determining ADRs from implants Regulation: First INDs given to hESC clinical trials (Geron/Reneuron), but continuing regulatory impasse in US (see blastocyst/blastomere) China and India’s engagement with international regulation Corporate: Emergence of user ‐ groups to respond to regulatory demands – establishment of ‘ATMP Bioprocessing Community ‘ in the UK Consolidation of primary hubs of activity in Europe (Germany, UK, F France) and US ) d US Greater engagement of big Pharma – Pfizer, AstraZeneca, GSK etc Clinical: Clinical: In Europe In Europe – steady growth of patient ‐ specific cell services model steady growth of patient specific cell services model seen as main therapeutic route for next decade (often via ‘hospital exemption’)

  6. Framing RM…its promise, boundaries and challenges A bio/cultural change ‐ ‘A…more malleable concept of biological limits,…a movable threshold between surplus and waste, obsolescence and renewal.’ (Cooper, 2006) A prospective change in practice: RM as Medicine 2.0 – A prospective change in practice: RM as Medicine 2.0 translation of science into clinical practice: ‘tissue engineering has been replaced by cell therapy’ with strong public support’ (Mason, 2007) A paradigm change in corporate/clinical relations? A paradigm change in corporate/clinical relations?

  7. Some key issues for the Conference: The geographical and technological stratification of the European RM sector, its • diverse (and highly uneven) markets, innovation strategies and its implications for appropriate policy ‐ making The distinctive innovation and governance models being developed in different • regions regions The specific challenges and risks associated with developing large ‐ scale trials in • the area and pressures towards harmonisation across Europe the area and pressures towards harmonisation across Europe The emergence of indirect forms of commercialization of oöcytes for reproductive • and research purposes and the regulatory challenges that need to be addressed here The emergence of distinctive and competing bioethical networks that frame RM in • very different ways. Overall: How to compare the UK/EU/US/and wider global developments?

Recommend


More recommend